MOG (35-55): Gold-Standard Peptide for Experimental Autoimmune Encephalomyelitis (EAE)

Executive Summary: MOG (35-55) is a truncated peptide derived from the myelin oligodendrocyte glycoprotein and serves as the benchmark inducer of experimental autoimmune encephalomyelitis (EAE) in murine models, which closely mimic multiple sclerosis (MS) pathogenesis (Xu et al. 2025). The peptide reliably elicits dose-dependent T and B cell immune responses, demyelination, and relapsing-remitting neurological symptoms. Its solubility and storage parameters are well-characterized, supporting reproducible workflows. MOG (35-55) is the standard for EAE induction and for evaluating neuroinflammation and therapeutic interventions (APExBIO). Mechanistic studies, including NADPH oxidase and MMP-9 modulation, clarify its functional role in oxidative stress pathways and matrix remodeling.

Biological Rationale

Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by immune-mediated demyelination in the central nervous system (CNS) (Xu et al. 2025). Experimental autoimmune encephalomyelitis (EAE) is the most widely accepted animal model for MS, capturing key pathological and clinical features. MOG (35-55), a peptide corresponding to amino acids 35–55 of human myelin oligodendrocyte glycoprotein, is the gold-standard agent for inducing EAE in susceptible rodent strains (see comparative overview). Its use allows researchers to reproducibly trigger CNS-specific autoimmunity, plaque-like demyelination, and neuroinflammation, reflecting the immunopathogenesis of human MS. This model is fundamental for dissecting autoimmune mechanisms and preclinical testing of MS therapies.

Mechanism of Action of MOG (35-55)

MOG (35-55) contains an immunodominant epitope recognized by both T and B cells in various mouse strains. Upon subcutaneous administration with complete Freund's adjuvant (CFA), the peptide is presented to autoreactive CD4+ T cells by antigen-presenting cells, initiating a type IV hypersensitivity response. The resulting activation of T helper (Th1 and Th17) populations leads to blood-brain barrier disruption, CNS infiltration, and demyelination (Xu et al. 2025). B cells produce anti-MOG antibodies, amplifying demyelination and inflammatory cascades. In vitro, MOG (35-55) increases NADPH oxidase and MMP-9 activity, which are markers of oxidative stress and extracellular matrix remodeling, respectively (APExBIO). These mechanisms underlie the clinical and pathological features observed in EAE models.

Evidence & Benchmarks

• Subcutaneous administration of MOG (35-55) at 50–150 μg per mouse, together with CFA, induces chronic or relapsing-remitting EAE with robust CNS demyelination (Xu et al. 2025, DOI).
• MOG (35-55) triggers both T cell proliferation and B cell-mediated autoantibody production in HLA-DR2-transgenic and C57BL/6 mice (APExBIO).
• In vitro, the peptide causes a dose-dependent decrease in protein concentration and increases NADPH oxidase and MMP-9 activities, signifying oxidative and matrix remodeling pathways (APExBIO).
• PARP7 inhibition, using the EAE model induced by MOG (35-55), stabilizes STAT1/STAT2 and relieves autoimmune neuroinflammation (Xu et al. 2025, DOI).
• The A8306 kit from APExBIO offers batch-to-batch consistency, supporting high reproducibility in EAE induction (see benchmark analysis).

This article extends the comparative analysis provided in "MOG (35-55): Data-Driven Solutions for Reliable Autoimmun..." by offering a detailed mechanistic insight and linking peptide function to translational assay outcomes.

Applications, Limits & Misconceptions

MOG (35-55) is essential for:

• Inducing EAE in mice to model human MS pathogenesis.
• Studying neuroinflammation, T and B cell immunity, and demyelination mechanisms.
• Preclinical testing of immunomodulatory drugs and genetic interventions targeting MS.
• Evaluating the effects of pathway modulators (e.g., PARP7 inhibitors) on neuroautoimmunity (Xu et al. 2025).

Common Pitfalls or Misconceptions

• Not effective in all rodent strains: Some strains (e.g., BALB/c) are resistant to MOG (35-55)-induced EAE, requiring alternative peptides or protocols (see strain-specific contrasts).
• Not a direct model for progressive MS: MOG (35-55) primarily induces relapsing-remitting or chronic EAE, but does not fully recapitulate progressive MS pathology.
• Requires adjuvant for efficacy: The peptide alone is insufficient; CFA is required to achieve robust immune priming and disease induction.
• Peptide degradation risk: Failure to prepare and store stock solutions desiccated at -20°C may lead to loss of activity.
• Insolubility in ethanol: Attempted preparation in ethanol will fail; use sterile water or DMSO as directed (APExBIO).

Workflow Integration & Parameters

Preparation: MOG (35-55) should be dissolved in sterile water at ≥32.25 mg/mL or in DMSO at ≥86 mg/mL; an ultrasonic bath and warming can improve solubility (APExBIO). Stock solutions are to be prepared at 0.50 mg/mL, stored desiccated at -20°C, and used promptly to prevent degradation.

Administration: For EAE induction, inject 50–150 μg per mouse subcutaneously, emulsified with CFA. Disease onset, severity, and progression are dose-dependent and strain-specific (see systems-level analysis).

Assay Integration: MOG (35-55) is compatible with clinical scoring, histopathology, flow cytometry, and molecular assays for immune and neural cell populations.

Conclusion & Outlook

MOG (35-55) remains the gold-standard myelin oligodendrocyte glycoprotein peptide for reproducible EAE induction and multiple sclerosis research. Its robust induction of CNS autoimmunity, well-characterized mechanism, and high batch-to-batch consistency (as supplied by APExBIO, A8306) make it indispensable for studies of neuroinflammation, autoimmunity, and therapeutic development. Ongoing developments, such as the identification of key regulatory pathways (e.g., PARP7-STAT1/2 axis), will further refine the utility of this model system (Xu et al. 2025).